Connect with us

Technology

POMDOCTOR LIMITED Advances Strategic Evolution from Traffic Monetization to Value-Based Healthcare Payment

Published

on

Building a Four-Tier Revenue Structure Across B2C Services, AI-Enabled Chronic Disease Management, B2B Healthcare Services, and Pharmaceutical RWS/RWD

GUANGZHOU, China, Nov. 4, 2026 /PRNewswire/ — POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today provided an overview of its strategic evolution and business model transformation amid the rapid development of China’s digital healthcare industry. Since its establishment in 2010, Pomdoctor has progressively evolved from the industry’s early “traffic monetization” model toward a more diversified and value-oriented healthcare ecosystem, culminating in its current four-tier revenue structure spanning B2C healthcare services, AI-enabled chronic disease management, B2B enterprise and hospital services, and pharmaceutical real-world study (“RWS”) and real-world data (“RWD”) services.

From Traffic Monetization to Diversified Healthcare Services

Pomdoctor was established in 2010, when China’s digital healthcare industry was entering an early stage of transformation. At the time, the prevailing business model centered on “traffic monetization,” with online consultations and pharmaceutical e-commerce generating revenue primarily through user acquisition, engagement, and pharmaceutical sales. As major participants from the e-commerce and pharmaceutical sectors entered the market, competition intensified, placing increasing pressure on the sustainability and differentiation of this model.

Recognizing the structural limitations of relying primarily on user traffic and pharmaceutical transactions, including patients’ limited willingness to pay directly for healthcare services, constrained health insurance coverage, and limitations in advertising-based monetization, Pomdoctor began developing a more diversified business model. The Company expanded beyond a purely service-oriented model and introduced subscription-based offerings supported by more refined operations and specialized healthcare services, establishing an early foundation for recurring and diversified revenue generation.

Expansion into B2B and Hospital Services

As the digital healthcare industry continued to evolve, Pomdoctor further expanded into B2B services, leveraging its healthcare expertise and digital capabilities to provide digital marketing solutions for pharmaceutical companies. Over time, this business evolved from pharmaceutical-focused digital services toward deeper engagement with healthcare institutions, including public hospitals.

This transition enabled Pomdoctor to broaden its role within the healthcare ecosystem, from serving individual users to connecting patients, healthcare providers, pharmaceutical companies, and other enterprise stakeholders. The Company believes this accumulated experience and institutional connectivity have provided an important foundation for its subsequent expansion into higher-value healthcare services.

Leveraging AI and Data to Unlock New Value

With the emergence of artificial intelligence (“AI”) as a transformative force across the healthcare industry, Pomdoctor has continued to build on its existing capabilities by developing and piloting AI-enabled healthcare programs with the objective of converting clinical applications into scalable, revenue-generating services. At the same time, the Company’s accumulated healthcare data assets have created opportunities for higher-value applications in chronic disease management, pharmaceutical research, and other data-driven healthcare services.

By integrating AI technologies, wearable devices, and its existing digital healthcare infrastructure, Pomdoctor is developing a more integrated ecosystem designed to connect patient services, chronic disease management, healthcare institutions, pharmaceutical companies, and data-driven applications. The Company believes this integrated approach can progressively transform data assets from primarily operational resources into sources of incremental commercial value. The Company’s AI-enabled chronic disease subscriptions and pharmaceutical RWS/RWD services are at an early stage of commercialization.

Building a Four-Tier Revenue Structure

Pomdoctor’s current business model is structured around four interconnected revenue tiers:

B2C Basic Healthcare Services — providing an entry point for patients and users through core digital healthcare services;AI-Enabled Chronic Disease Membership Subscriptions — extending user relationships through personalized, technology-enabled chronic disease management and recurring subscription services;B2B Enterprise and Hospital Services — leveraging the Company’s healthcare capabilities and institutional relationships to provide digital solutions and services to enterprises and healthcare institutions; andPharmaceutical RWS/RWD Services — leveraging accumulated healthcare data, clinical experience, and AI capabilities to support pharmaceutical companies in real-world studies (“RWS”) and real-world data (“RWD”) applications.

Together, these four tiers are designed to create a progressive value chain rather than operate as independent revenue streams. B2C services provide the foundation for patient engagement and healthcare data accumulation; AI-enabled chronic disease subscriptions deepen patient relationships and enhance recurring revenue; B2B enterprise and hospital services broaden the Company’s institutional reach and commercial applications; and the resulting data and healthcare infrastructure create a foundation for higher-value pharmaceutical RWS/RWD services.

Pomdoctor believes this interconnected model is designed for longer-term growth opportunities, while creating a potential flywheel effect in which expanding users, healthcare services, institutional relationships, AI applications, and data assets reinforce one another and support the Company’s ongoing transition toward more value-based healthcare monetization.

Management Commentary

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: “Since our inception, we have continuously sought distinctive and sustainable ways to create value as the healthcare industry evolves through successive waves of business model and technological change. From our early focus on digital healthcare services, to the development of subscription-based offerings and B2B healthcare services, and now to AI-enabled chronic disease management and data-driven pharmaceutical services, we have consistently endeavored to invest ahead of emerging industry trends while building upon our existing capabilities.

“Today, Pomdoctor is focused on further strengthening our four-tier revenue structure and integrating these businesses into a more comprehensive healthcare ecosystem. We believe the combination of healthcare services, AI, institutional capabilities, and data assets provides a scalable foundation for our next stage of growth. With our experience and capabilities in China, we are also exploring opportunities to replicate and adapt this model in key international markets. We remain committed to continuously improving our business model, expanding our ecosystem, and translating our operational capabilities and innovation into sustainable long-term value for our shareholders.”

About POMDOCTOR LIMITED

POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company’s website: http://ir.7shiliu.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding: the Company’s strategic evolution from a traffic monetization model toward value-based healthcare payment and monetization; the Company’s plans to further strengthen its four-tier revenue structure spanning B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, and pharmaceutical RWS/RWD services, and to integrate these businesses into a more comprehensive healthcare ecosystem; the Company’s development and piloting of AI-enabled healthcare programs and its ability to convert clinical applications into scalable, revenue-generating services; the Company’s plans to integrate AI technologies, wearable devices and its existing digital healthcare infrastructure, and its belief that such integration can progressively transform data assets into sources of incremental commercial value; the Company’s expectations regarding growth in recurring subscription revenue, the expansion of its institutional reach and relationships with healthcare institutions, including public hospitals, and pharmaceutical companies, and the development of higher-value pharmaceutical RWS/RWD services; the Company’s belief that its interconnected business model is designed to balance near-term revenue generation and cash flow with longer-term growth opportunities and to create a potential flywheel effect; the Company’s exploration of opportunities to replicate and adapt its business model in key international markets; and the anticipated benefits of the Company’s strategy for patients, healthcare providers, pharmaceutical companies, shareholders and other ecosystem participants, including sustainable long-term value creation. Investors can identify many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “aims,” “estimates,” “projects,” “intends,” “plans,” “pursues,” “positions,” “will,” “would,” “should,” “could,” “may” or other similar expressions. These forward-looking statements are based on the Company’s current expectations, assumptions and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and investors are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements speak only as of the date of this announcement, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, except as may be required by law.

Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors and uncertainties. Investors are urged to review the section entitled “Item 3. Key Information—D. Risk Factors” in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 14, 2026, and the Company’s other filings with the SEC, which are available on the SEC’s website at www.sec.gov.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-advances-strategic-evolution-from-traffic-monetization-to-value-based-healthcare-payment-302927633.html

SOURCE POMDOCTOR LIMITED

Continue Reading

Technology

How Can Humanity Become Friends with the Ocean?

Published

on

By

BEIJING, Nov. 6, 2026 /PRNewswire/ — A news report from China.org.cn on China’s efforts in marine ecological governance:

“Look, white dolphins!” Such excited cries can often be heard along the coast of Xiamen, a city in east China’s Fujian Province.

The Indo-Pacific humpback dolphin, commonly known as the Chinese white dolphin, is considered Class I nationally protected wildlife in China. As apex predators in coastal waters, these dolphins are regarded as a barometer of marine ecosystem health. Back in the 1990s, however, rising shipping activity, coastal reclamation and near‑shore development severely encroached on their habitats.

To minimize disturbances to dolphin habitats, Xiamen established China’s first provincial‑level nature reserve dedicated to Chinese white dolphins in 1997. Since then, the city has continuously refined its coastal governance approaches, restricted activities with significant environmental impacts, and promoted cross‑regional collaboration in conservation. Many other ocean‑friendly initiatives have also been rolled out. These include restoring mangrove wetland ecosystems; implementing an “offshore sanitation” mechanism and organizing public beach‑clean‑up campaigns to regularly remove floating marine debris; and releasing nearly 8 billion aquatic animals across 18 species through stock enhancement programs. As a result, populations of several fish species, such as the wild large yellow croaker and yellowfin seabream, have returned to Xiamen Bay.

Recently, “AI bodyguards” have joined the conservation effort. High‑definition cameras, drones and intelligent recognition systems track dolphin activity round‑the‑clock. Automatic alerts are issued whenever vessels approach the dolphins in violation of regulations. Researchers have also created individual digital profiles for each dolphin, identifying them by their dorsal‑fin shapes and body spot patterns, while recording their movement trajectories.

Xiamen is a microcosm of China’s efforts in marine ecological governance — forging ahead boldly yet never walking alone.

Over the decades, China has taken a series of concrete steps: from founding its first marine nature reserve in 1963, to proposing the goal of “building a strong maritime nation,” and publishing the white paper “Marine Eco‑Environmental Protection in China”; from drawing marine ecological protection red lines, to actively engaging with the UN Decade of Ocean Science for Sustainable Development and signing major international agreements on marine conservation, including the UN Agreement on Biodiversity Beyond National Jurisdiction (UN BBNJ).

For decades, China has been answering a vital question through concrete action: how can humanity coexist harmoniously with the ocean and create mutual benefits?

The answer is becoming increasingly clearer. Today, China’s extensive coastline features clean waters and pristine beaches, with fish swimming freely and seabirds soaring overhead. Not long ago, China’s Blue Bay Restoration Initiative was named a UN World Restoration Flagship. Now, the 21st Xiamen World Ocean Week is officially inaugurated, bringing together experts, scholars and representatives from various countries and international organizations to discuss marine conservation and harmonious coexistence between humanity and the ocean. In marine ecological protection and governance, China is not only a proactive participant and practitioner, but also a contributor to sharing experience and shaping future approaches.

Along Xiamen’s shoreline, the sea breeze blows gently as children run after the waves, echoing the ongoing story of humanity and the ocean.

China Mosaic
http://www.china.org.cn/video/node_7230027.htm

View original content to download multimedia:https://www.prnewswire.com/news-releases/how-can-humanity-become-friends-with-the-ocean-302932059.html

SOURCE China.org.cn

Continue Reading

Technology

OneStream Surpasses 600 EMEA Customers and Triples AI Adoption

Published

on

By

OneStream triples AI customer base and deepens investment across EMEA as Founder and CEO Tom Shea presents governed Finance AI framework at Web Summit

LISBON, Portugal, Nov. 6, 2026 /PRNewswire/ — OneStream, the AI operating system for modern Finance that unifies core financial and operational processes, embedding the governance, context, and control required to make AI work for Finance, today announced it has surpassed 600 customers in EMEA and more than tripled its Finance AI customers in the region since the end of 2025. The news comes as Founder and CEO Tom Shea takes the stage at Europe’s biggest tech event, Web Summit 2026, to detail a framework for auditable, contextualized AI for Finance.

“CFOs across Europe are realizing the real advantage of AI isn’t the smartest model – it’s AI operating within a strict framework of financial governance,” said Tom Shea, Founder and CEO at OneStream. “AI is the reasoning engine, but enterprise software must be the trust engine. Our acceleration in EMEA proves leaders want a financial control tower that delivers answers they can act on without operational risk. We will continue investing heavily in the local teams and partners helping them build this secure foundation.”

Accelerating EMEA Momentum
Over the past 12 months, OneStream helped more than 100 new EMEA customers modernize their tech stack and passed 600 customers in the region, with customers in more than 35 markets. Customers span industries including manufacturing, retail, banking and financial services, pharmaceuticals, and oil and gas. Notable EMEA customers include Grupo ACS, Delivery Hero, and Swatch.

Customers across the region are using OneStream to modernize core Finance processes, replacing fragmented legacy systems with a unified platform for financial close, consolidation, reporting, and planning. This unified foundation helps teams keep pace with complex regulatory requirements across EMEA, while providing the governed data necessary to leverage AI for accelerated insights and real business value.

OneStream’s Finance AI adoption is growing alongside its broader platform growth. The number of EMEA customers using OneStream’s Finance AI has more than tripled since the end of 2025.

To support this sustained regional acceleration, OneStream continues to scale its operations and partner ecosystem, building on its established regional presence across London, Manchester, Paris, Amsterdam, and Madrid.

“Finance leaders across EMEA are modernizing their core Finance platforms to keep pace with complex regulation and move faster,” said Matt Rodgers, EVP, EMEA at OneStream. “That modernization is what enables them to take AI from pilots to enterprise-wide deployment, because it gives them a data foundation they can actually trust. Our momentum in the region underscores a fundamental shift toward governed, unified enterprise platforms that deliver real business value.”

Building Trust in AI Agents

Shea will appear in a featured fireside chat titled “Why AI and SaaS Need Each Other” on Thursday, Nov. 12, at 1:25 PM on Stage 7. Moderated by Hope King, Founder of Macro Talk, and featuring Luminance CEO Eleanor Lightbody, the session will examine the evolving role of enterprise software as AI agents take on increasingly complex workflows. Shea will detail how governed data, strict access controls, and transparent audit trails determine how safely organizations can let autonomous agents act on their own.

To learn more about Shea’s session at Web Summit, click here.

About OneStream

OneStream is the AI operating system for modern Finance that unifies core financial close, planning, and operational processes and data, in one intelligent platform, all embedded with the governance, context, and control required to make AI work for Finance.

With over 1,900 customers, including 16% of the Fortune 500, a strong ecosystem of go-to-market, implementation, and development partners and 1,600 employees, we empower the Office of the CFO to become a critical driver of business strategy and execution. To learn more, visit onestream.com.

Media Contact

Jaclyn Proctor
Media Relations Contact
OneStream
media@onestreamsoftware.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/onestream-surpasses-600-emea-customers-and-triples-ai-adoption-302931403.html

SOURCE OneStream, Inc.

Continue Reading

Technology

Insilico Open-Sources 24/7 Personal Longevity Superintelligence to Turn Quantified-Self Data into Predictive Health States and Aging Research

Published

on

By

CAMBRIDGE, Mass., Nov. 6, 2026 /PRNewswire/ — Insilico Medicine, a clinical-stage generative AI drug discovery company, today announced the open-source release of Longevity Grok, the Personal Longevity Superintelligence (PLSI) and launched the website longevitygrok.si, in collaboration with leading geroscience researcher David Sinclair from Harvard Medical School. Developed for the Grok Bot platform, PLSI is an open-source, multi-agent AI system designed to unify fragmented personal health records, track biological analysis, formulate personalized lifestyle interventions, predict and score post-intervention biomarker changes, as well as drive communal AI-powered geroscience research.

For decades, health management and longevity medicine have been hampered by severe data fragmentation. Laboratory blood panels, continuous glucose monitoring, wearable streams, epigenetic assays, and clinical records sit across disconnected portals, leaving patients unable to follow their biological trajectory and clinicians working from incomplete histories. Modern healthcare turns to LLMs to close that gap, however, without persistent, auditable memory or follow-up on if advice actually improves outcomes, they rarely outperform traditional methods.

Personal Longevity Superintelligence (PLSI) addresses this gap with a continuous, 24/7 automated research loop. It converts fragmented medical data into a standardized longitudinal health trajectory and generates accountable, predictive guidance through a multi-agent architecture. The system continuously forecasts health risks, proposes interventions, and scores outcomes through closed-loop feedback.

Running within Grok Bot’s secure environment, it coordinates a team of up to 30 specialized AI agents, standardizes heterogeneous records with clinical coding systems such as LOINC, RxNorm, and UCUM, and uses always-on routines to monitor longevity science updates, organize incoming data, and keep the personal health state current without constant re-prompting. The same system is framed for three complementary roles:

As a personal longevity assistant, PLSI turns scattered labs, wearables, epigenetic assays, and clinical files into a unified, audit-ready health trajectory on the user’s device. It proposes lifestyle, nutritional, or longevity interventions with an auditable “prediction card” (target biomarker, confidence interval, time horizon, and evidence grade), evaluates each plan through an agent-driven adversarial review. When follow-up results arrive, PLSI scores whether outcomes fall within the predicted interval, confirms direction, and tracks calibration over time, turning each choice into a checkable N-of-1 experiment. Users can also voluntarily allocate unused daily token quota to Idle Research in the background to find new ways to increase their lifespan.

As a physician’s assistant, PLSI supplies structured longitudinal context instead of fragmented PDFs and portal exports. Standardized representations and a coherent biological trajectory help clinicians better organize their workflow Prediction cards and evidence grades aid in decision-making, while closed-loop scoring after follow-up supports auditable discussion of response and adherence. PLSI also features safeguards that overrule AI discretion to keep  formal diagnosis and prescriptions solely with licensed physicians.

As a partner for aging research, PLSI extends individual tracking into communal discovery. Users may opt in to contribute consented, deidentified trajectories to Longevity Mothership via an anonymous relay with an irrevocable kill switch to purge records on demand. Idle Research is a modern take on volunteer computing platforms , such as Folding@home, which let autonomous researcher agents scan literature, formulate hypotheses, and design analyses based on  public databases to accelerate target discovery and other anti-aging discovery activities.

Across all three roles, privacy is the default: a zero-trust architecture keeps raw medical files and identifiable clinical records in the user’s environment , unless the user explicitly opts into communal research. Both the PLSI Client and the Longevity Mothership backends are fully open-source and freely available on GitHub for review and contribution. Both setups feature data controller agents, which scrub the data at egress and intake points to prevent entry re-identification.

PLSI is available to all Grok Bot users and can be installed by instructing your bot with the following one-liner:

Set yourself up using https://github.com/Insilico-org/plsi 

The agentic skills and code are provided as an open-source package which can be inspected and modified by all, according to their needs.

“Longevity Grok turns Grok Bot into an open platform where individuals, physicians, and scientists can use AI to better understand their health, predict the effects of interventions, and find ways to live longer, healthier lives,” said David A. Sinclair, Ph.D., Professor of Genetics and Co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. “What makes this exciting is that people can contribute to scientific discovery while improving their own health, helping us understand why we age and how we might slow or even reverse it.”

“Currently, there are zero tools that are clinically proven to give a healthy person an additional year of life if they are already dieting, exercising, sleeping, and getting regular diagnostics,” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine. “Longevity Grok is a distributed system designed around a personal research space where you can work with your own data to optimize your health, longevity, and peak-span trajectories. As this system diffuses into the community, we expect to achieve longevity superintelligence, enabling a vast network of individuals to conduct autonomous research on their own biology while utilizing shared computation resources to pursue advanced longevity experiments. Aging is the only inescapable constraint on human freedom, and pushing this frontier is about giving people the optionality to remain young, healthy, and productive for as long as possible.”

Longevity has been central to Insilico’s mission since its inception. The company’s path drew industry attention in 2015 at the NVIDIA GTC conference, where Alex Zhavoronkov, Ph.D., founder and CEO of Insilico, challenged the tech world with a provocative question: “Can NVIDIA cure aging?” In 2014, Insilico established the annual Aging Research and Drug Discovery (ARDD) meeting, now widely regarded as a leading academic gathering for geroscience and biogerontology. The 13th ARDD, held at Harvard University in 2026, brought together leading academic investigators, pharmaceutical executives, and clinical pioneers to translate longevity discoveries into actionable medicine.

In 2026, Insilico accelerated the translation of AI-driven longevity research from experimental theory to transformative biological interventions. In April, the company announced the industry’s first longevity board of high-profile scientists, chaired by Andrew Adams, Ph.D., Group Vice President of Molecular Discovery at Eli Lilly and Company, to advance AI-driven aging research for drug discovery. In September, Insilico open-sourced an AI longevity toolkit, including LongevityBench, Longevity-LLMs, and LongevityClaw, with collaborators in a Cell cover study, accelerating research and therapeutic development. That publication follows Insilico’s contemporaneous Nature Biotechnology paper, in which Rentosertib, the company’s most advanced AI-driven pipeline candidate, showed biological age reversal according to Phase IIa clinical data across six independent proteomic aging clocks.

Since 2014, Insilico has published more than 50 research papers on aging and longevity, aging biomarkers, therapeutic targets, and therapeutics implicated in aging, longevity, and disease.

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma. AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.

For more information, please visit www.insilico.com

View original content:https://www.prnewswire.com/news-releases/insilico-open-sources-247-personal-longevity-superintelligence-to-turn-quantified-self-data-into-predictive-health-states-and-aging-research-302931941.html

SOURCE Insilico Medicine

Continue Reading

Trending